Clinical Trial Update: The Efficacy and Drug Resistance Molecular Biology of Apatinib Combined With EGFR-TK1 Treated for Advanced Slow-progressed Non-Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy and resistance mechanisms of combining apatinib with an EGFR tyrosine kinase inhibitor for advanced slow-progressing non-s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Apatinib (apatinib)
• EGFR-TK1 (EGFR tyrosine kinase inhibitor)

Snippet

Sponsor: Beijing Chest Hospital | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN